InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.39
(
0.00%
)
US TECH 100
18,144.00
(
0.49%
)
Dow Jones
39,357.01
(
-0.36%
)
Brent Oil
81.77
(
0.20%
)
Bitcoin
58,859.78
(
-0.84%
)
Post# of 252864
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120262
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ThomasS post# 114841

Tuesday, 02/15/2011 7:48:59 PM

Tuesday, February 15, 2011 7:48:59 PM

Post# of 252864
From the same article:

A year ago, the company was lucky to be selling $5 million a year in products.

Actually, a year ago MNTA was not selling anything—its revenue was from in-house R&D reimbursed by NVS.

The trajectory of the profit performance is remarkable, reports Robert Auer, senior portfolio manager of the SBAuer Funds.

Well, duh, that kind of thing can happen when a drug is approved for marketing. Geez.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up